1. The fate in the pregnant New Zealand White rabbit of oral doses of four 14C-labelled hydrolysis products of thalidomide, namely a-(o-carboxybenzamido)-glutarimide, 2-phthalimidoglutaramic acid, 2-phthalimidoglutaric acid and 2-(o-carboxybenzamido)glutaramic acid, administered on the 192nd hour of pregnancy has been studied. 2. About 60-95% of the administered 14C of each compound appears in the urine in 58hr. and the remainder is found in the faeces and in the gut and its contents. 3. Radioactivity is present in the plasma, liver, kidney, brain, muscle, fat and embryo. 4. The '40-labelled substances in the plasma and embryo consist of the unchanged compounds and their further hydrolysis products. 5. Since the above four thalidomide hydrolysis products are found in the rabbit conceptus together with their further hydrolysis products after their oral administration to the pregnant rabbit, it appears that the teratogenic activity ofthalidomide is due to the compound itself rather than to one or more of its hydrolysis products.
In the preceding paper (Fabro, Smith & Williams, 1967) it was shown that, after the oral admiinistration of thalidomide to rabbits at the 192nd hour of pregnancy, the drug itself and seven of its hydrolysis products are to be found in the embryo. These products were found to accumulate in the embryo and to persist for more than 58hr. after dosing. The teratogenic effects ofthalidomide could be due therefore to the drug itself or to one or more of these products. However, the hydrolysis products have been found to be non-teratogenic in rabbits (Fabro, Schumacher, Smith, Stagg & Williams, 1965; Keberle et al. 1965a; Keberle, Loustalot, Maller, Faigle & Schmid, 1965b) , but this lack of teratogenicity could be due to an inability to penetrate into the embryo on oral administration, for these products are all fairly polar compounds. The fate of oral doses of four of these compounds labelled with 14C has been investigated in pregnant rabbits when given at the sensitive period. The compounds were 2-phthalimidoglutaramic acid, a-(o-carboxybenzamido)glutarimide, 2-phthalimidoglutaric acid and 2-(o-carboxybenzamido)glutaramic acid. It is shown below that these compounds do penetrate into the embryo when given by mouth to the mother.
MATERIALS AND METHODS
The non-radioactive hydrolysis products used have been described by . (Sondheimer & Holley, 1957) was suspended in dry methanol (50ml.) and hydrogenated for 2hr. at atmospheric pressure in the presence of palladium black (500mg.). After filtration the solution was evaporated to dryness at 400 in a rotary evaporator. The residue of a-aminoglutarimide dissolved in dry pyridine (lOml.) was treated with [carbonyl-14C] 
Animals and procedures
Adult New Zealand White does (body wt. 3-4kg.) as described in the preceding paper (Fabro et al. 1967) were used. Each compound, except (± )-2-(['4C]o-carboxybenzamido)glutaramic acid, which was already in solution (see above), was given orally, suspended in water (20ml.), at a dose of 150mg./kg. (5tzc/kg.) to rabbits at the 192nd hour of pregnancy and appropriate groups of animals were killed at 12, 24 and 58hr. after dosing. The collection of exereta, the sampling of tissues and embryos, the measurement of 14C and the identification of compounds were carried out as described in the preceding paper (Fabro et al. 1967) . RESULTS ae-([14C]o-Carboxybenzamido)glutarimide. Table 1 shows that about 80% of the 14C from an oral dose of this compound is excreted in the urine during the sensitive period of 58hr., and a further 10% occurs in the faeces and the gut and its contents. The 24hr. urines collected from rabbits 13 and 14 were further examined and it was found that about 33% of the dose of 14C occurs as unchanged oc-(o-carboxybenzamido)glutarimide, about 26% as 2-plus 4-(ocarboxybenzamido)glutaramic acids and 3% as 2-(o-carboxybenzamido)glutaric acid. The plasma 14C concentration reaches a maximum at 4hr. after dosing and then declines, and at 58 hr. it is about 25% of the maximum (Fig. 1) . The plasma radioactivity is higher at 12, 24 and 58 hr. than that of other tissues, including the embryo, except the kidney ( Table 2 ). The embryo '4C/plasma 14C concentration ratio is about 0-6 at 12, 24 and 58hr. after dosing. The maternal plasma and embryo contain at 24hr. after dosing a-(o-carboxybenzamido)glutarimide (3.9,ug./ml. and 1-9,ug./g. respectively), 2-and 4(o-carboxybenzamido)glutaramic acids (1-4 ,ug./ml. and 09 ,ug./g. respectively), 2-(o-carboxybenzamido)glutaric acid (0.2 pg./ml. and 0.2,g./g. respectively) and phthalic acid (0-1,ug./ml. and 0-1,utg./g. respectively). These values are the means of three experiments.
2-[14C]Phthalimidoglutaramic acid. At 12 hr. after the oral administration of this compound to pregnant rabbits about 50% of the 14C is found in the urine and 40% in the gut and its contents (Table 3) . At 24 and 58hr., however, the urinary excretion of radioactivity is variable (57-84% of the dose). Similarly, the amounts found in the faeces (1.7-9-5%) and in the gut and its contents (1-0-29-8%) are variable. In the 24hr. urine, 48% of the dose is found as the unchanged compound, 5-9% as 2-phthalimidoglutaric acid, 3.6% as 2-(o-carboxybenzamido)glutaramic acid, 3.7% as 2-(o-carboxy- Vol. 104 * The specific activity of the embryo with its membranes and of the yolk-sac fluid were determined in these cases and found to be the same. (48); 2-phthalimidoglutaric acid (5.9); 2-(o-carboxybenzamido)glutaramic acid (3.6); 2-(o-carboxybenzamido)glutaric acid (3 7); phthalic acid (0 4). benzamido)glutaric acid and 0.4% as phthalic acid. The plasma 14C concentration reaches a maximum at about 8hr. after dosing (Fig. 1) . At 12, 24 and 58hr. after dosing the plasma 14C concentration is higher than that found in other tissues except the kidney (Table 4) . The embryo 1'C/plasma 14C concentration ratio is in the range 0 35-0 075. The maternal plasma and embryo contain at 24hr. after dosing 2-phthalimidoglutaramic acid (5 8,ug./ml. and 2.5,ug./g. respectively), 2-phthalimidoglutaric acid (0.1 ,ug./ml. and 0 1 ,ug./g. respectively), 2-(ocarboxybenzamido)glutaramic acid (0. 7 g./ml. and 0.4,g./g. respectively) and 2-(o-carboxybenzamido)glutaric acid (0.4p,g./ml. and 0*1 ,ug./g. respectively). These values are the means of three experiments.
2[14C]-Phthalimidoglutaric acid. When this acid is administered orally to pregnant rabbits about 90% of the 14C is excreted in the urine in 24hr. and about 5% is found in the faeces and in the gut and its contents. About a half of the dose of this acid is excreted unchanged in the urine in 24hr. but 23% of the dose appears as 2-(o-carboxybenzamido)-glutaric acid (Table 5 ). The plasma 14C concentration is highest at 4hr. after dosing and then rapidly declines, and at 24hr. only traces of 14C are found in the plasma (Fig. 1) . The maternal plasma. and embryo contain at 8hr. after dosing 2-phthalimidoglutaricacid (4.7 ,ug./ml. and2.8 ,g./g. respectively), 2-(o-carboxybenzamido)glutaric acid (0 4,ug./ml. and 0 3,ug./g. respectively) and phthalic acid (<0. 1,g./ml. and <0 1,ug./g. respectively).
These values are the means of three experiments.
2-([14C]o-Carboxybenzamido)glutaramic
acid. After the oral administration of this compound to rabbits at the 192nd hour of pregnancy, about 58%
of the 14C appears in the urine in 24hr. and 34% in the faeces and gut and its contents. Analysis of the 24hr. urine shows that about 47% of the dose is excreted unchanged, together with small amounts of 2-(o-carboxybenzamido)glutaric acid (2-4%) and phthalic acid (7.9%) ( Table 6 ). The plasma 14C
concentration is highest at about 8hr. after dosing and at 24hr. it has dropped to about half the maximum value (Fig. 1) . Table 7 shows the tissue distribution of 14C at 24hr. after an oral dose of the glutaramic acid. The plasma 14C concentration is greater than that ofthe embryo and maternal tissues except the kidney. The maternal plasma and embryo contain at 24hr. after dosing 2-(o-carboxybenzamido)glutaramic acid (4.0,ug./ml. and 572 1967 3-6,ug./g. respectively), 2-(o-carboxybenzamido)-glutaric acid (<0-1 ,ug./ml. and <0-1 ug./g. respectively) and phthalic acid (0-5,ug./ml. and 0-3 ,ug./g. respectively) . These values are the means of three experiments. DISCUSSION In the preceding paper (Fabro et al. 1967 ) it was shown that, if thalidomide is given orally to pregnant rabbits at the time when the embryo is sensitive to the teratogen, the drug itself and seven of its hydrolysis products are present in the conceptus at 12 and at 24hr. after dosing. In fact, at 12hr. after treatment the concentration of the hydrolysis products in the embryo is about nine times that of thalidomide. These findings raise the question of the significance of the presence in the embryo of these hydrolysis products in the teratogenic action of thalidomide. The hydrolysis products of thalidomide do not appear to be teratogenic in the pregnant rabbit when given by mouth Smith et al. 1965; Keberle et al. 1965a,b) , but these findings are not conclusive since it is not known whether the hydrolysis products, when given orally, can penetrate into the embryo. Indeed, little is known about the transmission offoreign compounds from the mother to the embryo during morphogenesis. The present work shows that, of the seven hydrolysis products of thalidomide that have been found in the rabbit embryo after the oral administration of the drug to the mother, four, namely ac-(o-carboxybenzamido)glutarimide (I), 2-phthalimidoglutaramic acid (II), 2-phthalimidoglutaric acid (III) and 2-(o-carboxybenzamido)glutaramic acid (IV), can penetrate into the conceptus when given to the mother by mouth. Further, two other hydrolysis products, namely 4-(o-carboxybenzamido)glutaramic acid and 2 -(o -carboxybenzamido)glutaric acid, have been found in the rabbit embryo after some of these products have been given. Thus 4-(o-carboxybenzamido)glutaramic acid is found in the embryo after the administration of a-(o-carboxybenzamido)glutarimide, and 2-(ocarboxybenzamido)glutaric acid is present in the embryo after the administration of 2-phthalimidoglutaramic acid, ac-(o-carboxybenzamido)glutar-573 Vol. 104
